JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy-Reference-Cited by-同舟云学术

JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy

Published:2016-02-29 Issue:8 Volume:30 Page:1772-1775
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Barosi G,Klersy C,Villani L,Bonetti E,Catarsi P,Poletto V,Campanelli R,Impera S,Latagliata R,Viarengo G,Carolei A,Massa M,Musso M,Crescimanno A,Gale R P,Rosti V

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201645.pdf

Reference12 articles.

1. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799–807.

2. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787–798.

3. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108: 1497–1503.

4. Barosi G, Vannucchi AM, De Stefano V, Pane F, Passamonti F, Rambaldi A et al. Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper. Leuk Res 2014; 38: 155–160.

5. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703–1708.

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature;Expert Opinion on Pharmacotherapy;2024-07-02

2. Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements;Cancers;2024-01-25

3. Molecular markers as possible efficacy predictors of targeted therapy for myelofibrosis: single-center study;Oncohematology;2023-12-08

4. Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments;Cancers;2023-06-24

5. Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy;Expert Opinion on Pharmacotherapy;2023-05-29